Clinical Trial

Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors

Study acronym: HEMO-CONNECT
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This pilot prospective study aims to evaluate adherence to home blood pressure monitoring using connected blood pressure (BP) devices in patients with malignant B-cell hemopathies initiating covalent Bruton tyrosine kinase inhibitors (cBTKi). The objective is to determine whether digital BP monitoring improves early detection and management of BTKi-induced hypertension over 6 months.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2026-05-11; most recent amendment 2026-06-18.
Trial Details
NCT Number NCT07592481
Lead Sponsor Centre Hospitalier de la côte Basque
Conditions Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL), Waldenstrom Macroglobulinaemia, Lymphoplasmacytic Lymphoma, Marginal Zone B Cell Lymphoma, Mantle Cell Lymphoma
Enrollment 40 participants
Start Date 2026-07-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-22